Teva Pharma Signs Material Definitive Agreement
Ticker: TEVJF · Form: 8-K · Filed: Jun 25, 2024 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $750 million, $500 million, $250 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
Related Tickers: TEVA
TL;DR
Teva just signed a big deal, details TBD.
AI Summary
Teva Pharmaceutical Industries Ltd. entered into a material definitive agreement on June 23, 2024. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.
Why It Matters
This filing signals a significant new contract or partnership for Teva, which could impact its future revenue streams and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Registrant
- June 23, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement Teva Pharmaceutical Industries Ltd. entered into?
The filing does not specify the nature of the agreement, only that it is a material definitive agreement.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the identity of the other party involved in the agreement.
What is the effective date of this material definitive agreement?
The earliest event reported, which is the entry into the agreement, is dated June 23, 2024.
Are there any financial terms or obligations associated with this agreement disclosed in the filing?
No, the filing does not provide any details regarding financial terms or obligations.
Does this agreement represent an acquisition, divestiture, or partnership for Teva?
The filing does not specify whether the agreement is an acquisition, divestiture, or partnership.
Filing Stats: 636 words · 3 min read · ~2 pages · Grade level 16.7 · Accepted 2024-06-25 08:01:01
Key Financial Figures
- $750 million — ill pay a total amount of approximately $750 million to the ITA spread over years 2024 throu
- $500 million — otal amount includes: (i) approximately $500 million in corporate taxes with respect to the
- $250 million — Investment Law; and (ii) approximately $250 million in corporate taxes, relating to additio
Filing Documents
- d839417d8k.htm (8-K) — 23KB
- 0001193125-24-167489.txt ( ) — 139KB
- teva-20240623.xsd (EX-101.SCH) — 3KB
- teva-20240623_lab.xml (EX-101.LAB) — 17KB
- teva-20240623_pre.xml (EX-101.PRE) — 11KB
- d839417d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: June 25, 2024 By: /s/ Eli Kalif Name: Eli Kalif Title: Executive Vice President, Chief Financial Officer